Clinical Impact of Enhanced Recovery After Esophagectomy in Patients With Esophageal Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 12 06 2023
revised: 12 07 2023
accepted: 13 07 2023
medline: 1 9 2023
pubmed: 31 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

The enhanced recovery after surgery (ERAS) program is expected to improve perioperative outcomes in patients with esophageal cancer. However, how ERAS impacts the postoperative body composition and factors related to compliance rate of ERAS have not been fully investigated. The study included 252 consecutive patients with thoracic esophageal cancer who underwent minimally invasive esophagectomy. We compared the postoperative outcomes including body composition between the old perioperative program and the new one that aimed to shorten postoperative length of stay (LOS). Compliance-related clinical factors were also examined. From 252 patients, 129 underwent the old program and 123 the new program. Postoperative LOS, postoperative complications, and hospital costs were reduced with the new program. Body weight loss was significantly improved with the new program at discharge and 3-months after esophagectomy (94.9% vs. 96.6%, p=0.013, 89.5% vs. 91.1%, p=0.028, respectively). Patients in the new program had better body composition at discharge than those in the old program [body fat mass (91.6% vs. 94.1%), lean body mass (95.2% vs. 97.2), and skeletal muscle mass (95.3% vs. 97.0%)]. Major reasons for incompliance were dysphagia, pneumonia, and anastomotic leakage. Multivariate analysis revealed that age ≥70 years at surgery and sex (male) were independent risk factors for incompliance with the postoperative program. The new ERAS program aimed to shorten postoperative LOS had clinical benefits in body composition early after esophagectomy. Personalized ERAS programs based on age might lead to better postoperative outcomes because of low compliance rates for older patients.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The enhanced recovery after surgery (ERAS) program is expected to improve perioperative outcomes in patients with esophageal cancer. However, how ERAS impacts the postoperative body composition and factors related to compliance rate of ERAS have not been fully investigated.
PATIENTS AND METHODS METHODS
The study included 252 consecutive patients with thoracic esophageal cancer who underwent minimally invasive esophagectomy. We compared the postoperative outcomes including body composition between the old perioperative program and the new one that aimed to shorten postoperative length of stay (LOS). Compliance-related clinical factors were also examined.
RESULTS RESULTS
From 252 patients, 129 underwent the old program and 123 the new program. Postoperative LOS, postoperative complications, and hospital costs were reduced with the new program. Body weight loss was significantly improved with the new program at discharge and 3-months after esophagectomy (94.9% vs. 96.6%, p=0.013, 89.5% vs. 91.1%, p=0.028, respectively). Patients in the new program had better body composition at discharge than those in the old program [body fat mass (91.6% vs. 94.1%), lean body mass (95.2% vs. 97.2), and skeletal muscle mass (95.3% vs. 97.0%)]. Major reasons for incompliance were dysphagia, pneumonia, and anastomotic leakage. Multivariate analysis revealed that age ≥70 years at surgery and sex (male) were independent risk factors for incompliance with the postoperative program.
CONCLUSION CONCLUSIONS
The new ERAS program aimed to shorten postoperative LOS had clinical benefits in body composition early after esophagectomy. Personalized ERAS programs based on age might lead to better postoperative outcomes because of low compliance rates for older patients.

Identifiants

pubmed: 37648293
pii: 43/9/4197
doi: 10.21873/anticanres.16611
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4197-4205

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Takahito Sugase (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Takashi Kanemura (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Tomohira Takeoka (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Shinya Urakawa (S)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Keijiro Sugimura (K)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
Department of Gastroenterological Surgery, Kansai Rosai Hospital, Amagasaki, Japan.

Yasunori Masuike (Y)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Naoki Shinno (N)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Hisashi Hara (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Takeshi Omori (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Masatoshi Kitakaze (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Masahiko Kubo (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Yosuke Mukai (Y)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Toshinori Sueda (T)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Shinichiro Hasegawa (S)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Hirofumi Akita (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Junichi Nishimura (J)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Hiroshi Wada (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Masayoshi Yasui (M)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Hiroshi Miyata (H)

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan; hiroshi.miyata@oici.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH